



Spread of Clonally Related *Escherichia coli* Strains Harboring an IncA/C₁ Plasmid Encoding IMP-8 and Its Recruitment into an Unrelated MCR-1-Containing Isolate

Alan Elena,^{a,b} Daniela Cejas,^{a,b} Francisco Magariños,^c Virginia Jewtuchowicz,^c Andrea Facente,^c Gabriel Gutkind,^{a,b} José Di Conza,^{a,b} Marcela Radice^{a,b}

^aUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Microbiología, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

^bConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina

^cHospital Interzonal de Agudos Luisa C de Gandulfo, Buenos Aires, Argentina

ABSTRACT Ten IMP-8-producing *Escherichia coli* isolates were recovered from surveillance cultures of a neonatal intensive care unit; eight of the isolates were clonally related. A 168.2-kb *bla*_{IMP-8} plasmid was fully sequenced, and it corresponded to the recently described IncA/C1-ST13 plasmid. This plasmid was detected in all isolates, even in those that were not clonally related. One unrelated isolate was also resistant to colistin and positive for *mcr-1*. This marker was located in a 62.7-kb IncI2 plasmid, which was also fully sequenced.

KEYWORDS *Escherichia coli*, IMP-8 metallo-beta-lactamase, IncA/C1 plasmid, IncI2 plasmid, *mcr-1*

The emergence and spread of carbapenemase-producing bacteria are major concerns for public health systems worldwide. IMP-type metallo-β-lactamases (MBLs) were first identified in the early 1990s in *Pseudomonas aeruginosa* in Japan and since then have been globally reported, mostly in *P. aeruginosa* and in other nonfermenting Gram-negative bacilli (1). Studies performed in Argentina reported the presence of IMP-13 in *P. aeruginosa* and IMP-8 in *Enterobacter cloacae* (2–4). IMP-8 was initially described in *Klebsiella pneumoniae* in Taiwan, where it became the dominant MBL among *Enterobacteriaceae* (5). The presence of the *bla*_{IMP-8} gene was reported in nosocomial and environmental *E. coli* isolates in association with conjugative plasmids belonging to IncA/C and IncFIB, respectively. As in other MBL-coding genes, *bla*_{IMP-8} was found to be located in a class 1 integron (4–6).

The rising frequency of carbapenem-resistant *Enterobacteriaceae* infections prompted the use of colistin as a last therapeutic option. However, the scenario became more complex as a consequence of the silent spread of plasmid-carried *mcr-1* in the past decade (7, 8).

The aim of this study was to characterize carbapenem-resistant *E. coli* isolates recovered from the active surveillance cultures of a neonatal intensive care unit (NICU) at a hospital in Buenos Aires, Argentina. Surveillance cultures are routinely conducted on patients admitted to the NICU in this hospital. During November to December 2016, 10 carbapenem-resistant *E. coli* isolates were recovered from seven patients on CHROMagar KPC (*K. pneumoniae* carbapenemase). Antibiotic susceptibility was assessed by microdilution tests according to the CLSI guidelines and the use of automated systems (Vitek 2, bioMérieux, France). All isolates were found to be resistant to trimethoprim-sulfamethoxazole and cephalosporins, with intermediate susceptibility or resistance to imipenem and/or meropenem (9). Nine of the 10 isolates were resistant to amikacin, gentamicin, and ciprofloxacin, and they displayed a wild-type phenotype

Received 5 December 2017 Returned for modification 2 January 2018 Accepted 20 March 2018

Accepted manuscript posted online 16 April 2018

Citation Elena A, Cejas D, Magariños F, Jewtuchowicz V, Facente A, Gutkind G, Di Conza J, Radice M. 2018. Spread of clonally related *Escherichia coli* strains harboring an IncA/C₁ plasmid encoding IMP-8 and its recruitment into an unrelated MCR-1-containing isolate. *Antimicrob Agents Chemother* 62:e02414-17. <https://doi.org/10.1128/AAC.02414-17>.

Copyright © 2018 American Society for Microbiology. All Rights Reserved. Address correspondence to Marcela Radice, marcelaradice@gmail.com.

with respect to colistin (i.e., they were susceptible according the EUCAST guidelines). The one remaining isolate was categorized as non-wild type for colistin (i.e., resistant according the EUCAST guidelines), and it was intermediate for aminoglycosides and ciprofloxacin (Table 1) (9). All isolates showed a positive synergy test result with EDTA (1 μ mol), suggesting the presence of an MBL (10, 11). PCR amplifications for the most common MBL-coding genes were conducted with specific primers and plasmid DNA as the template (11–13). Nucleotidic sequences of the amplified fragments showed 100% identity with *bla*_{IMP-8} for all samples. This marker was located on a conjugative plasmid, which was successfully transferred to *E. coli* CAG 12177. According to a PCR-based replicon typing method proposed previously, the plasmid corresponded to the IncA/C group, similarly to those seen in isolates previously reported in Singapore (5, 14).

*bla*_{IMP-8} was located in a 168.2-kb plasmid, which was purified by the standard plasmid DNA phenol-chloroform purification protocol initially proposed by Kado and Liu, adding two extraction steps performed with chloroform to remove any remaining phenol (15). Purified plasmids were fully sequenced by the use of a MiSeq sequencer (Illumina). The sequencing reads were assembled using SPAdes V3.9 with the following statistical parameters: largest contig, 153,183 bp; N50, 90,320 bp; L50, 2. The plasmid presented 227 open reading frames and had an average of 50.3% G+C content. Genes were predicted and annotated using the RAST tool and PROKKA software and were also manually curated (GenBank accession no. [AN] [MG550958](https://ncbi.nlm.nih.gov/GenBank/record/CP021058)) (16). Using the ResFinder tool, other resistance markers such as *bla*_{TEM-1B}, *aadA1*, *aph(3')Vla*, and *sul1* were detected in the same plasmid. *bla*_{IMP-8} was associated with a class 1 integron flanked by two IS26 elements. The *bla*_{IMP-8}-carrying integron lacked the typical 3' conserved sequence (*qacEΔ1* and *sul1*) but instead harbored a truncated sequence of a retron-type RNA-directed DNA polymerase (maturase), which has been reported to be likely involved in cassette gene generation (17, 18) (Fig. 1). The genetic platform for *bla*_{IMP-8} was confirmed in all isolates by PCR mapping and sequencing performed with the primers shown in Fig. 1. Plasmid multilocus sequence typing (pMLST) was performed to determine the IncA/C replicon type (<https://pubmlst.org/plasmid/>). The IncA/C₁ replicon, detected in this plasmid, was coincident with data corresponding to the recently deposited sequence type 13 (ST13) plasmid from *Citrobacter freundii*, which was isolated 20 years ago in Argentina. These plasmids are closely related to the ST11 IncA/C₁ RA1 plasmid and to the recently published ST12 (19, 20).

As previously mentioned, one isolate (*E. coli* G3216) was also colistin resistant and rendered a positive PCR result for *mcr-1*; this gene was located in a conjugative plasmid that was successfully transferred to *E. coli* CAG 12177. In accordance with previous reports, the full sequence of the *mcr-1*-harboring plasmid (pG3216) showed that *mcr-1* was flanked upstream by *pap2* (type 2 phosphatidic acid phosphatase) and downstream by the relaxase NikB-coding gene (GenBank AN [MF693349](https://ncbi.nlm.nih.gov/GenBank/record/MF693349)). This plasmid was 62.7 kb in size and presented 88 open reading frames with an average of 42.5% G+C content. It did not harbor any further resistance gene and was almost identical (99% identity) to that previously reported in our country (GenBank AN [KY471314](https://ncbi.nlm.nih.gov/GenBank/record/KY471314)) (21). Using the PlasmidFinder tool, pG3216 was found to be associated with the IncI2 group. Hence, *hicA* and *hicB*, which are related to the IncI2 incompatibility group and involved in type II toxin-antitoxin (TA) systems, were identified (22). The coding genes for the toxin RelE and the antitoxin StbE, which belong to the RelE/ParE TA system superfamily, were located together (23). Similarly to other IncI2 plasmids, pG3216 displayed a typical backbone responsible for plasmid replication, maintenance, and self-transfer by conjugation (24).

The *E. coli* phylogenetic group was determined according to the method previously described by Clermont et al. (25), and all of the isolates corresponded to phylogroup D (25). The clonal relationship was investigated by the use of XbaI-pulsed-field gel electrophoresis (XbaI-PFGE) and MLST (http://enterobase.warwick.ac.uk/species/ecoli/allele_st_search). Eight of the 10 isolates were clustered in pulsotype I and did not correspond to any of the assigned sequence types (*adk* 332, *fumC* 594, *gyrB* 428, *icd* 517, *mdh* 292, *purA* 373, *recA* 262). *E. coli* G1216 presented a different pulsotype

TABLE 1 Clinical data and microbiological characteristics of bla_{IMP-8}-harboring isolates^c

Newborn	Bacterial isolate/day of isolation ^b /no. of days of NICU stay before isolation	Treatment/no. of days of treatment	Risk factor/GA/wt of newborn (g) wks/870	Antimicrobial susceptibility (MIC [μ g/ml]) ^c														Pulsotype
				AM	AMS	PTZ	FEP	CAZ	CTX	IMP	MEM	GEN	AKN	CIP	COL	TMS		
1	G2116/1/89	MEM/21, COL/21, VAN/21	Preterm birth/30 wks/870	>32	>32	>128	>64	>64	>64	8	16	>16	>64	1	2	>320	I	
2	G1116/13/40 G1216/28/56 G1316/41/69	AM/10, GEN/7, CTX/5, AKN/5, COL/8	Preterm birth/28 wks/1,260	>32	>32	>128	16	>64	>64	4	8	>16	>64	1	1	>320	I	
3	G4116/28/41	AM/10, GEN/7	Term birth/40 wks/3,370	>32	>32	>128	>64	>64	>64	8	16	>16	>64	1	1	>320	I	
4	G3116/28/8 G3216/41/21	CTX/4, AKN/4	Term birth/38 wks/3,210	>32	>32	>128	>64	>64	>64	8	8	>16	>64	1	2	>320	I	
5	G6116/43/16	AM/5, GEN/5	Preterm birth/34 wks/2,060	>32	>32	>128	>64	>64	>64	2	8	>16	>64	1	1	>320	I	
6	G7116/43/28	VAN/12, MEM/12	Preterm birth/32 wks/1,610	>32	>32	128	>64	>64	>64	2	8	>16	>64	1	1	>320	I	
7	G5116/49/41		Preterm birth/37 wks/2,500	>32	>32	>128	>64	>64	>64	2	8	>16	>64	1	1	>320	I	

^aAM, ampicillin; AMS, ampicillin-sulbactam; PTZ, piperacillin-tazobactam; FEP, cefepime; CAZ, ceftazidime; CTX, cefotaxime; IMP, imipenem; MEM, meropenem; GEN, gentamicin; AKN, amikacin; CIP, ciprofloxacin; COL, colistin; TMS, trimethoprim-sulfamethoxazole; VAN, vancomycin; GA, gestational age.

^bFor the data representing the day of isolation, day 1 corresponds to the index case; the other days of isolation were determined with respect to that of the index case.

^cMICs for IMP, MEM, and COL were assessed by manual procedures, whereas those of the others were assessed by automated methods (Vitek 2). Data corresponding to the mcr-1-harboring isolate are indicated in bold.




FIG 1 Genetic context of plasmid-borne *bla*_{IMP-8} detected in this study (MG550958). The primers used for PCR mapping were as follows: IMP-F1B (GTTTTGTAGCATTGCTACCGCAG) and IMP-AR (GTTTTGCCTTACC ATATTTGGA), IS26-F (TCACTCCACGATTTACCGCT) and IS26-R (CTTACCAGGCGCATTTCGCC), Int1B (GCGT TCGGTCAAGTCTTGG) and Int1C (CGTGATGCTTGTCTTA), and 5'CS (GCTTGCTGCTTGGATGCC).

(pulsotype II), which corresponded to, among others, a single-locus variant (SLV) of ST69 (CC69) (*adk* 21, *fumC* 35, *gyrB* 27, *icd* 6, *mdh* 286, *purA* 5, *recA* 4). The *mcr-1*-positive *E. coli* G3216 isolate represented pulsotype III, which corresponds to a SLV of ST5377 and ST7395 (*adk* 35, *fumC* 37, *gyrB* 29, *icd* 25, *mdh* 416, *purA* 564, *recA* 73). These results indicate that the isolates included in this study do not belong to the STs in which *bla*_{IMP-8} was previously reported (ST131, ST359, ST457, and ST410) (5, 26).

Despite the fact that IMP-8-producing *Enterobacteriaceae* are frequently detected in Asia, in our country (Argentina), they have been encountered only sporadically (4). Both CHROMagar KPC and EDTA-based synergy tests were useful to perform early and accurate detection of colonized neonates with MBL-producing *E. coli*, thereby contributing to the reduction of the spread of such microorganisms and probably of the subsequent infections. *E. coli* phylogroup D includes extraintestinal pathogens and multidrug-resistant isolates (27). Although these strains are reported to be responsible for severe diseases, none of the seven neonates included in this study developed IMP-8 *E. coli* infections. Moreover, none of them received antibiotic treatment for this colonization and all of them were medically discharged. Dissemination of *E. coli* which produced IMP-8 MBL and belonged to pulsotype I occurred in this neonatal ward until hygiene measures and contact isolation were strengthened. It can be speculated that horizontal transmission of the *bla*_{IMP-8} Inc A/C₁ plasmid may have occurred, as this marker was also detected in the unrelated isolates; *E. coli* G1216 (pulsotype II) recovered from a patient also colonized with pulsotype I *E. coli* and *E. coli* G3216 (pulsotype III), which also harbored the IncI2 plasmid containing *mcr-1* (Table 1). Furthermore, the class 1 integron platform containing *bla*_{IMP-8} could be self-mobilized as it was flanked by two identical IS26 copies, which could act as composite transposons (28).

Plasmid-mediated colistin resistance, commonly found in carbapenem-susceptible strains, has also been reported in *Enterobacteriaceae* producing different carbapenemases such as VIM-1, VIM-2, NDM-5, NDM-9, IMP-4, KPC-2, and OXA-48 (29–35). In our country, *mcr-1* was previously described both in clinical isolates and in poultry farms (8, 36). Here, we have described the presence of *mcr-1* in a *bla*_{IMP-8}-producing *E. coli* isolate, which adds an extra level of plasticity in the evolving epidemiology of carbapenem and colistin resistance.

Our results highlight the importance of establishing screening schemes and rapid laboratory diagnostic tests to ensure the implementation of efficient infection control measures.

Accession number(s). The complete sequences of the plasmids analyzed in this study have been deposited at DDBJ/EMBL/GenBank under accession numbers [MG550958](#) and [MF693349](#).

ACKNOWLEDGMENTS

We thank V. Pebe for his collaboration and for providing the clinical data.

This study was supported by UBACyT grants to M.R. and G.G. (20020150100174BA and 20020130100432BA), by PICT grants to M.R., G.G., and D.C. (2013-0858, 2015-1925, and 2015-2844), and by PIP grant 11220120100400CO to G.G. and M.R.

REFERENCES

- Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. 1991. Transferable imipenem resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 35:147–151. <https://doi.org/10.1128/AAC.35.1.147>.
- Gomez S, Rapoport M, Togneri A, Viegas-Caetano J, Faccione D, Corso A, Petroni A, Pasteran F. 2011. Emergence of metallo-beta-lactamases in Enterobacteriaceae from Argentina. *Diagn Microbiol Infect Dis* 69:94–97. <https://doi.org/10.1016/j.diagmicrobio.2010.08.025>.
- Santella G, Cuirolo A, Almuzara M, Palombarani S, Sly G, Radice M, Gutkind G. 2010. Full resistance and decreased susceptibility to carbapenems in IMP-13-producing *Pseudomonas aeruginosa* isolates from an outbreak. *Antimicrob Agents Chemother* 54:1381–1382. <https://doi.org/10.1128/AAC.00399-09>.
- Togneri AM, Gomez SA, Podesta LB, Perez MP, Faccione DF, Rios LE, Ganetea MA, Anchordoqui MS, Pasteran FG, Corso AC. 2013. Dissemination of *bla*_{IMP-8} among Enterobacteriaceae isolates from a Buenos Aires hospital. *Rev Argent Microbiol* 45:104–109. (In Spanish.)
- Koh TH, Cao D, Tee NW, Teo JW. 2014. *Escherichia coli* with *bla*(IMP-8) in Singapore. *Antimicrob Agents Chemother* 58:617. <https://doi.org/10.1128/AAC.01754-13>.
- Kieffer N, Poirel L, Bessa LJ, Barbosa-Vasconcelos A, da Costa PM, Nordmann P. 2016. VIM-1, VIM-34, and IMP-8 carbapenemase-producing *Escherichia coli* strains recovered from a Portuguese river. *Antimicrob Agents Chemother* 60:2585–2586. <https://doi.org/10.1128/AAC.02632-15>.
- Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis* 16:161–168. [https://doi.org/10.1016/S1473-3099\(15\)00424-7](https://doi.org/10.1016/S1473-3099(15)00424-7).
- Dominguez JE, Figueroa Espinosa RA, Redondo LM, Cejas D, Gutkind GO, Chacana PA, Di Conza JA, Fernandez-Miyakawa ME. 2017. Plasmid-mediated colistin resistance in *Escherichia coli* recovered from healthy poultry. *Rev Argent Microbiol* 49:297–298. <https://doi.org/10.1016/j.ram.2017.02.001>.
- CLSI. 2017. Performance standards for antimicrobial susceptibility testing. vol 37, approved standard M100. Clinical and Laboratory Standards Institute, Wayne, PA.
- Arakawa Y, Shibata N, Shibayama K, Kurokawa H, Yagi T, Fujiwara H, Goto M. 2000. Convenient test for screening metallo-beta-lactamase-producing gram-negative bacteria by using thiol compounds. *J Clin Microbiol* 38:40–43.
- Pagniez G, Radice M, Cuirolo A, Rodriguez H, Vay C, Famiglietti A, Gutkind G. 2006. Prevalence of metallo-beta-lactamase in carbapenem resistant *Pseudomonas aeruginosa* at a university hospital of Buenos Aires City. *Rev Argent Microbiol* 38:33–37.
- Cejas D, Almuzara M, Santella G, Tuduri A, Palombarani S, Figueroa S, Gutkind G, Radice M. 2008. Phenotypic and genotypic characterization of imipenem-resistant *Pseudomonas aeruginosa* isolated in a Buenos Aires hospital. *Rev Argent Microbiol* 40:238–245. (In Spanish.)
- Poirel L, Dortet L, Bernabeu S, Nordmann P. 2011. Genetic features of *bla*_{NDM-1}-positive Enterobacteriaceae. *Antimicrob Agents Chemother* 55:5403–5407. <https://doi.org/10.1128/AAC.00585-11>.
- Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 2005. Identification of plasmids by PCR-based replicon typing. *J Microbiol Methods* 63:219–228. <https://doi.org/10.1016/j.mimet.2005.03.018>.
- Kado CI, Liu ST. 1981. Rapid procedure for detection and isolation of large and small plasmids. *J Bacteriol* 145:1365–1373.
- Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30:2068–2069. <https://doi.org/10.1093/bioinformatics/btu153>.
- Centrón D, Roy PH. 2002. Presence of a group II intron in a multiresistant *Serratia marcescens* strain that harbors three integrons and a novel gene fusion. *Antimicrob Agents Chemother* 46:1402–1409. <https://doi.org/10.1128/AAC.46.5.1402-1409.2002>.
- Sunde M. 2005. Class I integron with a group II intron detected in an *Escherichia coli* strain from a free-range reindeer. *Antimicrob Agents Chemother* 49:2512–2514. <https://doi.org/10.1128/AAC.49.6.2512-2514.2005>.
- Hancock SJ, Phan MD, Peters KM, Forde BM, Chong TM, Yin WF, Chan KG, Paterson DL, Walsh TR, Beatson SA, Schembri MA. 24 January 2017. Identification of *IncA/C* plasmid replication and maintenance genes and development of a plasmid multilocus sequence typing scheme. *Antimicrob Agents Chemother* <https://doi.org/10.1128/AAC.01740-16>.
- Esposito EP, Gaiarsa S, Del Franco M, Crivaro V, Bernardo M, Cuccurullo S, Pennino F, Triassi M, Marone P, Sasseria D, Zarrilli R. 2017. A novel *IncA/C1* group conjugative plasmid, encoding VIM-1 metallo-beta-lactamase, mediates the acquisition of carbapenem resistance in ST104 *Klebsiella pneumoniae* isolates from neonates in the intensive care unit of V. Monaldi hospital in Naples. *Front Microbiol* 8:2135. <https://doi.org/10.3389/fmicb.2017.02135>.
- Tijet N, Faccione D, Rapoport M, Seah C, Pasteran F, Ceriana P, Alborno E, Corso A, Petroni A, Melano RG. 2017. Molecular characteristics of *mcr-1*-carrying plasmids and new *mcr-1* variant recovered from poly-clonal clinical *Escherichia coli* from Argentina and Canada. *PLoS One* 12:e0180347. <https://doi.org/10.1371/journal.pone.0180347>.
- Li G, Shen M, Lu S, Le S, Tan Y, Wang J, Zhao X, Shen W, Guo K, Yang Y, Zhu H, Rao X, Hu F, Li M. 2016. Identification and characterization of the *HicAB* toxin-antitoxin system in the opportunistic pathogen *Pseudomonas aeruginosa*. *Toxins (Basel)* 8:113. <https://doi.org/10.3390/toxins8040113>.
- Unterholzner SJ, Poppenberger B, Rozhon W. 2013. Toxin-antitoxin systems: biology, identification, and application. *Mob Genet Elements* 3:e26219. <https://doi.org/10.4161/mge.26219>.
- Sun J, Li XP, Yang RS, Fang LX, Huo W, Li SM, Jiang P, Liao XP, Liu YH. 2016. Complete nucleotide sequence of an *IncI2* plasmid cohabiting *bla*_{CTX-M-55} and *mcr-1*. *Antimicrob Agents Chemother* 60:5014–5017. <https://doi.org/10.1128/AAC.00774-16>.
- Clermont O, Bonacorsi S, Bingen E. 2000. Rapid and simple determination of the *Escherichia coli* phylogenetic group. *Appl Environ Microbiol* 66:4555–4558. <https://doi.org/10.1128/AEM.66.10.4555-4558.2000>.
- Yan JJ, Tsai LH, Wu JJ. 2012. Emergence of the IMP-8 metallo-beta-lactamase in the *Escherichia coli* ST131 clone in Taiwan. *Int J Antimicrob Agents* 40:281–282. <https://doi.org/10.1016/j.ijantimicag.2012.05.011>.
- Clermont O, Christenson JK, Denamur E, Gordon DM. 2013. The *Escherichia coli* phylo-typing method revisited: improvement of specificity and detection of new phylo-groups. *Environ Microbiol Rep* 5:58–65. <https://doi.org/10.1111/1758-2229.12019>.
- He S, Hickman AB, Varani AM, Siguier P, Chandler M, Dekker JP, Dyda F. 2015. Insertion sequence IS26 reorganizes plasmids in clinically isolated multidrug-resistant bacteria by replicative transposition. *mBio* 6:e00762. <https://doi.org/10.1128/mBio.00762-15>.
- Du H, Chen L, Tang YW, Kreiswirth BN. 2016. Emergence of the *mcr-1* colistin resistance gene in carbapenem-resistant Enterobacteriaceae. *Lancet Infect Dis* 16:287–288. [https://doi.org/10.1016/S1473-3099\(16\)00056-6](https://doi.org/10.1016/S1473-3099(16)00056-6).
- Mulvey MR, Mataseje LF, Robertson J, Nash JH, Boerlin P, Toye B, Irwin R, Melano RG. 2016. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 16:289–290. [https://doi.org/10.1016/S1473-3099\(16\)00067-0](https://doi.org/10.1016/S1473-3099(16)00067-0).
- Poirel L, Kieffer N, Liassine N, Thanh D, Nordmann P. 2016. Plasmid-mediated carbapenem and colistin resistance in a clinical isolate of *Escherichia coli*. *Lancet Infect Dis* 16:281. [https://doi.org/10.1016/S1473-3099\(16\)00006-2](https://doi.org/10.1016/S1473-3099(16)00006-2).
- Yao X, Doi Y, Zeng L, Lv L, Liu JH. 2016. Carbapenem-resistant and colistin-resistant *Escherichia coli* co-producing *NDM-9* and *MCR-1*. *Lancet Infect Dis* 16:288–289. [https://doi.org/10.1016/S1473-3099\(16\)00057-8](https://doi.org/10.1016/S1473-3099(16)00057-8).

33. Falgenhauer L, Waezsada SE, Yao Y, Imirzalioglu C, Kasbohrer A, Roesler U, Michael GB, Schwarz S, Werner G, Kreienbrock L, Chakraborty T. 2016. Colistin resistance gene *mcr-1* in extended-spectrum beta-lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. *Lancet Infect Dis* 16:282–283. [https://doi.org/10.1016/S1473-3099\(16\)00009-8](https://doi.org/10.1016/S1473-3099(16)00009-8).
34. Zhang XF, Doi Y, Huang X, Li HY, Zhong LL, Zeng KJ, Zhang YF, Patil S, Tian GB. 2016. Possible transmission of *mcr-1*-harboring *Escherichia coli* between companion animals and human. *Emerg Infect Dis* 22:1679–1681. <https://doi.org/10.3201/eid2209.160464>.
35. Simon M, Melzl H, Hiergeist A, Richert K, Falgenhauer L, Pfeifer Y, Gerlach RG, Fuchs K, Reischl U, Gessner A, Jantsch J. 2017. Colistin- and carbapenem-resistant *Klebsiella oxytoca* harboring *blaVIM-2* and an insertion in the *mgrB* gene isolated from blood culture. *Int J Med Microbiol* 307:113–115. <https://doi.org/10.1016/j.ijmm.2017.01.001>.
36. Rapoport M, Faccione D, Pasteran F, Ceriana P, Albornoz E, Petroni A, Corso A. 2016. First description of *mcr-1*-mediated colistin resistance in human infections caused by *Escherichia coli* in Latin America. *Antimicrob Agents Chemother* 60:4412–4413. <https://doi.org/10.1128/AAC.00573-16>.